Abstract 187P
Background
The tumour microenvironment (TME) in high-grade serous ovarian cancer (HGSOC) is a complex ecosystem that facilitates ovarian cancer progression. However, further investigation is required to elucidate the precise role of the TME.
Methods
In this study, single-cell RNA sequencing was employed to profile the TME in freshly collected HGSOC samples, comprising two normal ovarian cortex samples and six HGSOC samples.
Results
A total of 55,430 single cells obtained from ovarian and HGSOC tissues were subjected to single-cell RNA sequencing (scRNA-seq). The cells were divided into seven clusters, comprising B cells, T and NK cells, myeloid cells, endothelial cells, fibroblasts, epithelial cells and mast cells. The proportion of B cells, myeloid cells, mast cells and T & NK cells was greater in HGSOC samples than in ovary cortex samples, whereas the percentage of epithelial cells was lower in the former. The analysis of intercommunication of epithelial cells with other cell clusters indicated that the interactions between epithelial cells and fibroblast cells, T & NK cells, B cells as well as myeloid cells were enhanced in in HGSOC samples comparing ovary cortex samples. Additionally, we identified a subcluster of epithelial cells (E7) and a subcluster of fibroblast cells (F7) that were implicated in tumour formation. Finally, we examined the intercommunication between E7 and F7. One of the most significant ligand-receptor signals identified was THBS2-CD74.
Conclusions
The results clearly demonstrated an increase in immune cell percentage in ovarian cancer tissue. Malignant cell clusters, designated as fibroblast cells F7 and epithelial cells E7, were also identified. Among the interactions between F7 and E7, the THBS2-CD74 signal emerged as a crucial factor in the tumourigenesis of HGSOC.
Legal entity responsible for the study
Beijing Obstetrics and Gynecology, Capital Medical University.
Funding
National Natural Science Foundation of China (No. 82373397), the Capital’s Funds for Health Improvement and Research (No. 2022-2-2116), Beijing Municipal Administration of Hospitals Incubating Program (No.PX2022057) and Beijing Obstetrics and Gynecology Hospital, Capital Medical University (No. FCYY201915).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
Resources:
Abstract
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
Resources:
Abstract
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
Resources:
Abstract
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
Resources:
Abstract
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
Resources:
Abstract
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
Resources:
Abstract
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
Resources:
Abstract
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
Resources:
Abstract
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session
Resources:
Abstract